Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications fo
Author: ["Robert Kisilevsky","Laura J. Lemieux","Paul E. Fraser","Xianqi Kong","Philip G. Hultin","Walter A. Szarek"]
Publication: Nature Medicine
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Amyloid is a term for extracellular protein fibril deposits that have characteristic tinctorial and structural properties. Heparan sulphate, or the heparan sulphate proteoglycan perlecan, has been identified in all amyloids and implicated in the earliest stages of inflammation-associated (AA) amyloid induction. Heparan sulphate interacts with the AA amyloid precursor and the β-peptide of Alzheimer's amyloid, imparting characteristic secondary and tertiary amyloid structural features. These observations suggest that molecules that interfere with this interaction may prevent or arrest amyloidogenesis. We synthesized low-molecular-weight (135–1,000) anionic sulphonate or sulphate compounds. When administered orally, these compounds substantially reduced murine splenic AA amyloid progression. They also interfered with heparan sulphate-stimulated β-peptide fibril aggregation in vitro.
Cite this article
Kisilevsky, R., Lemieux, L., Fraser, P. et al. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1, 143–148 (1995). https://doi.org/10.1038/nm0295-143
